loteprednol etabonate 0.25% ophthalmic suspension for Corneal Edema

"Affirmative. According to the clinicaltrials.gov website, this scientific trial is actively recruiting participants and opened on November 23rd 2021. As of now, 116 patients are being recruited at just one medical facility with its last update occurring on the 29th of November 2021."

"Affirmative. Clinicaltrials.gov contains data which demonstrates that this research endeavour is actively searching for participants, with the initial posting on November 23rd 2021 and a recent update on November 29th 2021. In total 118 individuals are needed from a single location."

"The research surrounding loteprednol etabonate 0.25% ophthalmic suspension began in 2021, when Price Vision Group funded the first trial of 116 participants. After passing through four stages of drug approval, it is now only subject to one active study sponsored by Price Vision Group."

"Loteprednol etabonate 0.25% ophthalmic suspension can be utilized to effectively address dry eye syndrome, associated discomfort, and other eye issues."

"Currently, there is one ongoing investigation into the efficacy of loteprednol etabonate 0.25% ophthalmic suspension with no studies in Phase 3. While Indianapolis houses multiple trials for this medication, at least one other site is recruiting patients to take part."

"Taking into account the fact that this is a Phase 4 medical trial, which implies that loteprednol etabonate 0.25% ophthalmic suspension has already been approved for use; our team at Power rated it with 3 out of 3 on safety scale."